维普期刊资源整合服务平台（V6.5）

32篇 您的检索式：作者名="Erlinger C"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Genetic variation of CYP2CI9 affects both pharmacokinetic and pharmacodynamic respon- ses to clopidogrel but not prasugrel in aspirin- treated patients with coronary artery disease显示文摘	VARENHORST C JAMES S ERLINGE D	2009	Eur Heart J2009，30，14：	1
2	Uridine triphosphate (UTP) is released during cardiac ischemia显示文摘	Erlinge D Harnek J van Heusden C Olivecrona G Jern S Lazarowski E	2005	Int J Cardiol2005，100，：	1
3	Genetic variation ofCYP2C19 affects both pharmacokinetic and pharmacodynamic re-sponses to clopidogrel but not prasugrel in aspirin treated patientswith coronary artery disease显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart J2009，30，14：	1
4	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic re sponses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D		0，，14：	1
5	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D		0，，14：	1
6	Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivn 显示文摘	Erlinge D Varenhorst C Braun O	2008	J Am Coil Cardio12008，52，24：	1
7	Uridine triphosphate (UTP) is released during cardiac ischemia 显示文摘	Erlinge D Harnek J Van Heusden C	2005	International journal of cardiology2005，100，3：	1
8	Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo显示文摘	ERLINGE D VARENHORST C BRAUN OO	2008	J Am Coll Cardiol2008，52，24：	1
9	Genetic variation of CYP2C19 affects both pharmaeokinetic and pharmacodyna- mic responses to clopidogrel but not prasugrel in aspirin- treated patients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart J2009，30，14：	1
10	Genetic variation of CYlY2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease 显示文摘	VARENHORST C JAMES S ERLINGE D	2009	Ear Heart J2009，30，17：	1
11	Geneticvariation of CYP2C19 affects both pharmacokinetic andpharmacodynamic responses to clopidogrel but not prasugrelin aspirin-treated patients with coronary artery disease 显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart /2009，30，14：	1
12	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmaeodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease 显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart J2009，30，14：	1
13	Current advances in the use of therapeutic hypothermia 显示文摘	Graffagnino C Erlinge D Keeble T	2015	Ther Hypothermia Temp Manag2015，5，1：	1
14	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart J2009，30，14：	1
15	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrcl but not prasugrel in aspirin-treated patients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D	2009	Eur Heart J2009，30，14：	1
16	Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo显示文摘	ERLINGE D VARENHORST C BRAUN OO	2008	J Am Coll Cardiol2008，52，24：	1
17	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmaeodynamic responses to clopidogrel but not rasugrel in aspirin-treated pa tients with coronary artery disease显示文摘	Varenhorst C James S Erlinge D et a l	2009	Eur Heart J2009，30，14：	1
18	Determining the Chemob- ylimpact on sediments of a pre-Alpine lake with a very compre- hensive set of data显示文摘	Erlinger C Lettner H Hubmer A	2008	Joumal of Environmental Radioactivity2008，99，8：	1
19	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease显示文摘	VARENHORST C JAMES S ERLINGE D	2009	Eur Heart J2009，30，14：	1
20	The combination of high sensitivity troponin T and copep- tin facilitates early rule-out of ACS: a prospective ob- servational study显示文摘	THELIN J BORNA C ERLINGE D	2013	BMC Cardiovasc Disord2013，13，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示